Arzneimittelnebenwirkungen – wie erkennen, wie vermeiden?

In der Arzneimitteltherapie gilt: keine Wirkung ohne Nebenwirkung. Manche Nebenwirkungen müssen die Patienten hinnehmen (z. B. Hand-Fuß-Syndrom). Nach gefährlichen Nebenwirkungen muss man suchen (Hyperkaliämie). Über die Sick-Day-Rule sollte mit den Patienten gesprochen und z. B. SGLT2-Inhibitoren sollten bei Übelkeit oder Schwindel pausiert werden. Notwendig ist auch die regelmäßige Medikationskritik mit dem Ziel, überflüssige oder riskante Medikamente abzusetzen (Deprescribing).

Abstract

There is no drug therapy without risk for toxicity. The patient must tolerate some toxic or idiosyncratic adverse events (e. g. hand foot syndrome). After life threatening adverse effects, one needs to screen (hyperkalemia). The sick-day-rule should be communicated with the informed patient as for example stopping SGLT2-inhibitors (loss of appetite, hypotension). The list of prescriptions should regularly criticized for dangerous or superfluous medicines (deprescribing).

Schlüsselwörter

Arzneimittel Toxizität - Idiosynkrasie - Pharmakodynamik - Sick-Day-Rule - Deprescribing

Key words

drug toxicity - idiosyncratic - pharmacodynamics - sick-day rule - deprescribing

Publication History

Article published online:
04 January 2021

• Literatur

• 1 Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond) 2016; 16 (05) 481-485
• 2 Adami HO, Berry SC, Breckenridge CB. et al. Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. Toxicol Sci 2011; 122 (02) 223-234
• 3 Castells M, Khan DA, Phillips EJ. Penicillin Allergy. Reply. N Engl J Med 2020; 382 (14) 1380
• 4 Wurpts G, Aberer W, Dickel H. et al. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG). Allergol Select 2020; 4: 11-43
• 5 Hirsch JS, Wanchoo R, Ng JH. et al. Use of immune Checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature. Kidney360 2020; 1 (05) 399-402
• 6 Heinzerling L, de Toni EN, Schett G. et al. Checkpoint Inhibitors. Dtsch Arztebl Int 2019; 116 (08) 119-126
• 7 Wang M, Munoz J, Goy A. et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020; 382: 1331-1342
• 8 Kächele M, Keller F. Pharmakokinetik und Pharmakodynamik bei extrakorporaler Nierenersatztherapie. Med Klin Intensivmed Notfmed 2020; DOI: 10.1007/s00063-020-00654-7.
• 9 Keller F with contributions from David Czock. Classical Pharmacokinetics and Concise Pharmacodynamics for Clinicians. Oberhaching-Munich: Dustri Verlag; 2019
• 10 Stürmer T, Erb A, Keller F. et al. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med 2001; 111: 521-527
• 11 Novick TK, Surapaneni A, Shin JI. et al. Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR. Clin J Am Soc Nephrol 2019; b14 (11) b1581-b1589
• 12 Hart E, Dunn TE, Feuerstein S. et al. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy 2019; 39 (04) 443-453
• 13 Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568
• 14 Krag M, Marker S, Perner A. et al. SUP-ICU trial group. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. N Engl J Med 2018; 379 (23) 2199-2208
• 15 Navarro V, Boulahfa I, Obach A. et al. Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A 10-Week Randomized Open-Label Study. J Clin Psychopharmacol 2019; 39 (03) 254-257
• 16 Santos-Gallego CG, Requena-Ibanez JA, San Antonio R. et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol 2019; 73 (15) 1931-1944
• 17 Cahn A, Raz I, Bonaca M. et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes – analyses from the DECLARE – TIMI 58 study. Diabetes Obes Metab 2020; 22 (08) 1357-1368